[Combination therapy in cardiovascular diseases other than XXXX ].

@entity712 @entity11115 @entity101 @entity19346 @entity3362 @entity1855 @entity117 @entity6478 @entity591 @entity951 @entity1188 @entity460 @entity551 @entity1482 @entity4144
As in @entity101 , the addition of a second active drug is believed to enhance treatment efficacy; however, the extent to which a combination of two low-dose drugs outperforms conventional monotherapy remains uncertain. Established treatments of @entity951 comprises @entity3362 compounds, beta-blockers and @entity460 antagonists, which are often given in combination. Beta-blockers are major players in this field as they inhibit the @entity591 induced by @entity3362 and @entity460 antagonists; there is therefore a pathophysiological justification for their use in combination therapy, supported by repeated confirmation of positive clinical effect. The most widely chosen @entity460 antagonists are @entity19346 ; @entity1855 may impair conduction. However, it is not clear whether combination enhances the effects of the individual antianginal substances. Diuretics are for most clinicians the keystone treatment of @entity712 ; diuretics are often combined with other drugs, e.g. @entity6478 and @entity1482 . The latter also have a beneficial effect on myocardial structure (myocardium/collagen ratio). ACE-inhibitors are of proven clinical efficacy, and, in addition, have a beneficial effect on survival. They combine well with diuretics: because the diuretic stimulates renin release, the ACE-inhibitor can be given at a lower dose (enhancement of effect). There are, however, certain drawbacks ( @entity551 , @entity4144 with antialdosterones). The results of combining ACE-inhibitors with @entity460 antagonists and beta-blockers await investigation. The ISIS studies demonstrated the advantages of combining beta-blockers, thrombolysis and @entity117 in acute @entity1188 . ACE-inhibitors have recently been added to the regimen with a positive effect (extended survival), especially in the presence of a decreased ejection fraction (SAVE, @entity11115 , GISSI 3 and ISIS 4 studies).(ABSTRACT TRUNCATED AT 250 WORDS)
